NFKB1 and Miyoshi myopathy: Because of its role in promoting cell growth and preventing apoptosis, and its frequent activation in MM via mutations in NF-kB cascade components, NF-kB signaling is a reasonable target for [multiple myeloma] chemotherapeutics [121].